The administration of the HMGB1-CRISPR/Cas9 KO plasmid during the chronic phase of CCH suppressed HMGB1 and proinflammatory cytokines (TNF-α, IL-1β, and IL-6). The gene discussed is IL6; the disease is columnar cell hyperplasia of the breast.